Laboratory Corporation of America 1st in US to offer blood-based CRC screening test: 4 key notes

Laboratory Corporation of America, a healthcare diagnostics, is the first United States-based laboratory to offer Epi proColon, a blood-based test for colorectal cancer screening.

Here are four key notes:

1. Epigenomics developed the test, and it is available in the U.S. through a joint commercialization agreement with Polymedco.

2. The Epi proColon test detects Epigenomics proprietary Septin9 DNA methylation biomarker for colorectal cancer in cell-free DNA circulating in blood.

3. The test was approved by the FDA in April.

4. Epi proColon provides an alternative to stool testing or colonoscopy.

More articles on GI/endoscopy:
FMT helps reduce recurring episodes of C. Diff in children: 4 findings
GIQuIC registry hits 3M colonoscopy cases: 5 things to know
Certain body sugars help prevent UC & colon cancer — 5 points

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months